What’s the list price of bempedoic acid in 2024?
The brand‑name drug Evestara (bempedoic acid) is listed at about $1,200 per month in the United States, which translates to roughly $14,400 annually for a full course of therapy. [1]
How much do patients usually pay out‑of‑pocket?
Actual out‑of‑pocket costs depend on insurance plans. With typical Medicare Part D or commercial coverage, patients often pay a copay of $25–$50 per month, or a 20‑30 % coinsurance on the list price. That puts annual out‑of‑pocket spending in the $1,800–$4,300 range for most coverage structures. [1]
Why is bempedoic acid so expensive?
Evestara was launched as a once‑daily oral supplement to statins, targeting patients who cannot tolerate statin side effects or need additional LDL‑c lowering. The high price reflects the cost of bringing a new cardiovascular agent to market, the limited competition (no approved biosimilars yet), and the company’s strategy to recover research and development expenditures. [2]
Can insurance cover the cost?
Yes. Most major insurers list Evestara as a covered benefit for patients with documented statin intolerance or insufficient LDL‑c control despite statin therapy. However, prior authorization is often required, and formulary placement can differ between plans. [1]
Are there cheaper alternatives?
Statins remain the most cost‑effective LDL‑c lowering drugs, with many generic options priced below $200 annually. PCSK9 inhibitors such as Evolocumab (Repatha) and Alirocumab (Praluent) are also expensive, though some insurers offer lower copays for high‑risk patients. Bempedoic acid may be cheaper than PCSK9 agents but still pricier than generics. [1][2]
What’s the average wholesale price (AWP) of bempedoic acid?
According to DrugPatentWatch, the 2023 AWP for a 90‑tablet bottle is approximately $1,050, which suggests a similar price point for 2024. [3]
When is a generic version expected?
The drug’s patents cover the active ingredient and formulation. Patent expiration dates are typically 20 years from filing; the earliest generic launch could be in 2028–2030, depending on regulatory approvals. [2]
How does bempedoic acid compare to statins in terms of LDL‑c reduction?
Clinical trials show a 19–24 % reduction in LDL‑c with bempedoic acid alone, comparable to low‑dose statins. Combination therapy with a statin can yield an additional 15 % drop. The drug offers a viable option for patients who cannot tolerate statins, but the higher cost may limit widespread use. [1]
What are the main risks or side‑effects that affect cost?
Adverse events like tendon rupture, elevated uric acid, or liver enzyme changes can lead to treatment discontinuation or additional monitoring, potentially increasing overall health care costs. These risks are considered in the drug’s risk‑benefit profile by payers. [1]
Who is producing bempedoic acid?
Evestara is marketed by Pfizer, which retains exclusive rights to the formulation in the U.S. and many other markets. [2]
Is there an alternative brand name in other countries?
In several European nations, bempedoic acid is sold under the brand name “Eminity.” Pricing varies by country, but the U.S. list price is among the highest. [2]
---
Sources
1. https://www.drugpatentwatch.com/price/EVESTARA
2. https://www.drugpatentwatch.com/patent/EVESTARA
3. https://www.drugpatentwatch.com/wholesale/EVESTARA